Association between FOXM1 expression and prognosis of non-small cell lung cancer: a meta-analysis

Long TIAN,Yutian LAI,Xin WANG,Kun ZHOU,Guowei CHE

DOI: https://doi.org/10.7507/1672-2531.201612023

2017-01-01

Abstract:Objective To systematically review the prognostic and clinicopathological value of FOXM1 expression in non-small cell lung cancer (NSCLC).Methods Databases including PubMed,EMbase,The Cochrane Library (Issue 1,2016),CNKI,WanFang Data and CBM were searched to collect cohort studies about the prognostic value of F OXM1 expression in NSCLC from inception to May 30th 2016.Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies.Then meta-analysis was performed by using RevMan 5.3 software.Results A total of 8 cohort studies,involving 781 patients were included.The results of meta-analysis showed that FOXM1 expression was higher in tumor stage Ⅲ to Ⅳthan stage Ⅰ to Ⅱ (OR=2.24,95％CI 1.25 to 4.01,P=0.007).Higher FOXM1 expression group had a shorter overall survival (HR=1.77,95％CI 1.42 to 2.22,P＜0.000 01) and diseasefree survival (HR=1.96,95％CI 1.04 to 3.17,P=0.04) than those of the lower FOXM1 expression group.Conclusion Current evidence shows that FOXM 1 expression is associated with NSCLC stage.Furthermore,FOXM 1 overexpression may be prognosis biomarker for NSCLC patients.Due to the limited quantity and quality of included studies,the above conclusions are needed to be verified by more high quality studies.